Clinical trials: Targeted Therapy, open to volunteers
Lung Cancer (NSCLC)
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT)…
- Trial name
- NCT06771960
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital
HER2-positive Breast Cancer, Metastatic Breast Cancer
SMP-656 for HER2-Positive Advanced Breast Cancer
The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor…
- Conditions
- HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- NCT07726342
- Testing
- SMP-656 Injection
- Where
- 15 sites in China
- Volunteers
- 60 people
- Sponsor
- Chengdu SciMount Pharmatech Co., Ltd.
Non Small Cell Lung Cancer
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
A prospective ,multicenter ,non-interventional ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in EGFRm NSCLC
- Trial name
- pre-FLAME (NCT06422546)
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Beijing Cancer Prevention & Treatment Society
Familial Chylomicronemia Syndrome (FCS)
CS-121 APOC3 Base Editing in FCS
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid…
- Trial name
- NCT07176923
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
This example planning study proposes a phase 1/2 evaluation of an allogeneic, cord-blood-derived dual-target CAR-NK product directed against CLDN18.2 and HER2 (ERBB2) in adults with unresectable or metastatic gastric or…
- Trial name
- DUET-GEJ (NCT07551362)
- Testing
- EB-DT-CAR-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Fibrillation, Atrial
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
- Trial name
- NOAC (NCT06874894)
- Where
- 2 sites in South Korea
- Volunteers
- 1,021 people
- Sponsor
- Chung-Ang University Hospital
Lung Cancer, Carcinoma, Squamous Cell
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes.
- Trial name
- GALAXY-02 (NCT06383728)
- Testing
- Osimertinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while…
- Trial name
- PASI (NCT07545902)
- Testing
- PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- ICIM International S.r.l.
Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis
- Trial name
- NCT07392528
- Testing
- QT-019C
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Huanhu Hospital
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
- Trial name
- NCT06355739
- Testing
- CAR T cell injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhu Xiaofan
Hyperkalaemia
AI-Enabled ECG Stratification and Timing of Potassium-Lowering Therapy in Patients With Hyperkalemia: A Target Trial Emulation Study
Hyperkalemia is a common and potentially life-threatening electrolyte disorder, yet there is limited evidence guiding the optimal timing of potassium-lowering therapy in routine clinical practice.
- Trial name
- AIDE-K (NCT07307729)
- Testing
- Timely treatment, Delayed treatment
- Volunteers
- 5,000 people
- Sponsor
- National Defense Medical Center, Taiwan
Mild Cognitive Impairment (MCI)
Working Memory Training in Patients with Mild Cognitive Impairment
The purpose of this study is to test whether a special memory training program, called CogMed, can help people with early memory problems.
- Trial name
- NCT06734286
- Testing
- CogMed
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Infections, Bacterial, Pharmacokinetics
Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
- Conditions
- Infections, Bacterial, Pharmacokinetics, Drug Monitoring, Drug-Related Side Effects and Adverse Reactions
- Trial name
- DATATDM (NCT06427317)
- Where
- United Kingdom
- Volunteers
- 323 people
- Sponsor
- Imperial College London
Advanced Pancreatic Cancer
Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.
This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer.
- Trial name
- NCT07416240
- Testing
- Claudin18.2 Targeted Activated Dendritic Cells, Claudin18.2 Targeted CAR-T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hainan Cancer Hospital
Hepatecellular Carcinoma
Affordable Made-in-India Microspheres for Liver Cancer Therapy
Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide…
- Trial name
- ReLIVE (NCT07436988)
- Testing
- 90Y-Theraspheres, 188Re-Microspheres
- Where
- 5 sites in India
- Volunteers
- 18 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Lung Adenocarcinoma, EGFR Activating Mutation
Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations.
- Trial name
- NCT06730477
- Testing
- observational study
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Myeloid Leukemia
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.
- Trial name
- NCT06746519
- Testing
- BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Chen Suning
Fuchs Endothelial Corneal Dystrophy
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
- Trial name
- NCT04440280
- Testing
- N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital